Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of IJC Heart & Vasculature
The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below.
-
1.
Impairment of left atrial function and cryptogenic stroke: Potential insights in the pathophysiology of stroke in the young [IJC Heart & Vasculature 26 (2020) 100454] https://doi.org/10.1016/j.ijcha.2019.100454
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
2.
Low-frequency and low-intensity ultrasound increases cardiac parasympathetic neural activity and decreases clinic hypertension in elderly hypertensive subjects with type 2 diabetes [IJC Heart & Vasculature 19 (2018) 34–36] https://doi.org/10.1016/j.ijcha.2018.04.002
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
3.
The sternal wire code; Solving the problem of missing coronary artery bypass graft records during cardiac catheterization [IJC Heart & Vasculature 19 (2018) 37–40] https://doi.org/10.1016/j.ijcha.2018.04.004
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
4.
Hypertrophic cardiomyopathy [IJC Heart & Vasculature 27 (2020) 100503] https://doi.org/10.1016/j.ijcha.2020.100503
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
5.
Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies [IJC Heart & Vasculature 22 (2019) 39–45] https://doi.org/10.1016/j.ijcha.2018.11.008
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
6.
Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives [IJC Heart & Vasculature 18 (2018) 52–57] https://doi.org/10.1016/j.ijcha.2018.02.005
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
7.
Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography [IJC Heart & Vasculature 18 (2018) 17–24] https://doi.org/10.1016/j.ijcha.2017.12.003
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
8.
Trimethylamine N-oxide in atrial fibrillation progression [IJC Heart & Vasculature 29 (2020) 100554] https://doi.org/10.1016/j.ijcha.2020.100554
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
9.
Computed tomography guided sizing for transcatheter pulmonary valve replacement [IJC Heart & Vasculature 29 (2020) 100523] https://doi.org/10.1016/j.ijcha.2020.100523
Declaration of competing interest: Dr Vaikom S Mahadevan is a principle investigator for pulmonic valve clinical trials for Edwards Life Sciences. No conflicts of interests for any of the other authors.
-
10.
Does combination therapy work in chronic thromboembolic pulmonary hypertension? [IJC Heart & Vasculature 29 (2020) 100544] https://doi.org/10.1016/j.ijcha.2020.100544
Declaration of competing interest: M. van Thor, J. Mager and M. Post report grants from Actelion Pharmaceuticals. J. Kelder has nothing to disclose. R. Snijder reports grants from Pfizer and Actelion Pharmaceuticals.
-
11.
Vernakalant and electrical cardioversion for AF – Safe and effective [IJC Heart & Vasculature 24 (2019) 100398] https://doi.org/10.1016/j.ijcha.2019.100398
Declaration of competing interest: No study specific funding was obtained; however some patients simultaneously participated in an ongoing post approval safety study (SPECTRUM) sponsored by Cardiome Pharma Corp. or were included in a RCT receiving limited grants by the Jubilaeumsfonds of the Austrian National Bank.
-
12.
Not typical angina and mortality in women with obstructive coronary artery disease: Results from the Women’s Ischemic Syndrome Evaluation study (WISE) [IJC Heart & Vasculature 27 (2020) 100502] https://doi.org/10.1016/j.ijcha.2020.100502
Declaration of competing interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: I, Dr. C. Noel Bairey Merz, serve as Board of Director for iRhythm, fees paid through CSMC from Abbott Diagnostics and Sanofi.